In conclusion, SHP2 appears to be a promising therapeutic target in combination treatment methods for NSCLC since it plays a critical positive regulatory function in the incidence, metastasis, immune evasion, and drug resistance of lung cancer, regardless of individual RTK/RAS mutational status. The gene discussed is PTPN11; the disease is non-small cell lung carcinoma.